- Open Access
Cytosolic phospholipase A2alpha amplifies early cyclooxygenase-2 expression, oxidative stress and MAP kinase phosphorylation after cerebral ischemia in mice
- Koji Kishimoto†1,
- Rung-Chi Li†1,
- Jian Zhang1,
- Judith A Klaus1,
- Kathleen K Kibler1,
- Sylvain Doré1,
- Raymond C Koehler1 and
- Adam Sapirstein1Email author
© Kishimoto et al; licensee BioMed Central Ltd. 2010
- Received: 30 November 2009
- Accepted: 30 July 2010
- Published: 30 July 2010
The enzyme cytosolic phospholipase A2 alpha (cPLA2α) has been implicated in the progression of cerebral injury following ischemia and reperfusion. Previous studies in rodents suggest that cPLA2α enhances delayed injury extension and disruption of the blood brain barrier many hours after reperfusion. In this study we investigated the role of cPLA2α in early ischemic cerebral injury.
Middle cerebral artery occlusion (MCAO) was performed on cPLA2α+/+ and cPLA2α-/- mice for 2 hours followed by 0, 2, or 6 hours of reperfusion. The levels of cPLA2α, cyclooxygenase-2, neuronal morphology and reactive oxygen species in the ischemic and contralateral hemispheres were evaluated by light and fluorescent microscopy. PGE2 content was compared between genotypes and hemispheres after MCAO and MCAO and 6 hours reperfusion. Regional cerebral blood flow was measured during MCAO and phosphorylation of relevant MAPKs in brain protein homogenates was measured by Western analysis after 6 hours of reperfusion.
Neuronal cPLA2α protein increased by 2-fold immediately after MCAO and returned to pre-MCAO levels after 2 hours reperfusion. Neuronal cyclooxygenase-2 induction and PGE2 concentration were greater in cPLA2α+/+ compared to cPLA2α-/- ischemic cortex. Neuronal swelling in ischemic regions was significantly greater in the cPLA2α+/+ than in cPLA2α-/- brains (+/+: 2.2 ± 0.3 fold vs. -/-: 1.7 ± 0.4 fold increase; P < 0.01). The increase in reactive oxygen species following 2 hours of ischemia was also significantly greater in the cPLA2α+/+ ischemic core than in cPLA2α-/- (+/+: 7.12 ± 1.2 fold vs. -/-: 3.1 ± 1.4 fold; P < 0.01). After 6 hours of reperfusion ischemic cortex of cPLA2α+/+, but not cPLA2α-/-, had disruption of neuron morphology and decreased PGE2 content. Phosphorylation of the MAPKs-p38, ERK 1/2, and MEK 1/2-was significantly greater in cPLA2a+/+ than in cPLA2α-/- ischemic cortex 6 hours after reperfusion.
These results indicate that cPLA2α modulates the earliest molecular and injury responses after cerebral ischemia and have implications for the potential clinical use of cPLA2α inhibitors.
- Middle Cerebral Artery Occlusion
- Reactive Oxygen Species Formation
- Anterior Cerebral Artery
- PGE2 Level
- PGE2 Concentration
Phospholipase A2 (PLA2) enzymes hydrolyze free fatty acids from the second position (sn-2) of membrane glycerophospholipids and augment neurologic injuries of oxidative stress (reviewed by Muralikrishna ). The cytosolic phospholipase A2α (cPLA2α, also known as PLA2 group IVA) is a member of the larger PLA2 superfamily and has unique properties that suggest it may regulate formation of eicosanoids in cell-signalling pathways. cPLA2α resides in the cytosol but translocates to intracellular membranes in response to physiologic Ca2+ changes . cPLA2α has a strong preference for hydrolysis of arachidonic acid (AA); is a major source of regulated, intracellular AA ; and is regulated by the protein kinase-dependent phosphorylation of several amino acids . We previously demonstrated that cPLA2α is a key effector of neurologic injury following cerebral ischemia and reperfusion (I/R) by showing that cPLA2α-/- mice have significantly less stroke injury than do wild-type littermate (+/+) mice after transient regional cerebral ischemia . The presence of cPLA2α in neurons  and its biochemical properties suggest that it could play a major regulatory role in neurologic signalling in ischemia and other neurologic diseases [7, 8].
cPLA2α also has a role in the regulation of the downstream enzymes that metabolize AA to the eicosanoids [9, 10], which are important mediators of acute and chronic neurologic injury in stroke . The role of COX-2 is particularly well-explored in cerebral I/R and is tightly correlated with cPLA2α. Inhibition or gene deletion of COX-2 decreases while COX-2 overexpression enhances neuronal injury following MCAO [12–14]. In mice cPLA2α expression appears to be necessary to maintain normal basal and induced expression of COX-2 in the brain [10, 15]. cPLA2α-derived arachidonic acid is also tightly coupled to the 5-lipoxygenase enzyme  and in the gerbil model of global cerebral ischemia 15 minutes of reperfusion caused translocation of 5-LO to the neuron membranes and resulted in increased levels of leukotriene C4 . cPLA2α amplifies the increase in permeability of the blood-brain barrier after transient ischemia , and eicosanoids contribute to the subsequent inflammatory responses . The eicosanoids, particularly prostaglandins (PGs), and AA itself may also contribute directly to the early excitotoxicity that precedes neuroinflammation [19–23]. Our lab and others found that cPLA2α can have a direct and early effect on excitotoxicity in vitro [19, 24, 25].
Here, we examined the effect of transient regional cerebral I/R on cPLA2α expression and, in turn, the effect of cPLA2α on cyclooxygenase (COX)-2 expression, PGE2 levels and reactive oxygen species (ROS) early in the cell-death cascade. We applied transient middle cerebral artery (MCA) occlusion (MCAO) to cPLA2α+/+ and cPLA2α-/- mice and investigated the effect of cPLA2α on early pathways of neurologic injury at 0, 2, and 6 hours of reperfusion. We then correlated cPLA2α expression with ROS generation and the phosphorylation of relevant MAPKs. Our results indicate that cPLA2α contributes to I/R injury immediately after ischemia.
Unless otherwise stated, all compounds were purchased from Sigma-Aldrich Company (St. Louis, MO). For immunomicroscopy anti-cPLA2α (P505) was purchased from Abcam Inc. (Cambridge, MA). Rabbit anti-cPLA2α (N-216) and anti-β-actin antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA). Alexa Fluor 488 and 568 donkey anti-rabbit IgG and NeuroTrace 435/455 Nissl Stain (NT) were purchased from Invitrogen Corporation (Carlsbad, CA).
All experiments were conducted in accordance with the guidelines of the National Institutes of Health and approved by the Johns Hopkins University Institutional Animal Care and Use Committee. cPLA2α+/- mice were a gift from Takao Shimizu (Tokyo University) and were supplied by Jim Clark (Wyeth Pharmaceutical, Cambridge, MA). Mice were housed in a facility with 12-hour diurnal light cycle with free access to food and water. All experimental mice were produced by mating male and female cPLA2α+/- mice that were produced and maintained in the C57BL/6J strain.
Focal Cerebral Ischemia
Transient focal ischemia was induced by MCAO in 10-14-week-old age-matched cPLA2α-/- and cPLA2α+/+ littermates between 20-28 g. Anesthesia was by spontaneous ventilation of isoflurane in 30% O2. A thermostatically controlled warming pad and infrared light were used to maintain the rectal temperature at 37.5 ± 0.5°C during all phases of the surgery. Left-sided MCAO and sham surgery were performed as previously described . After 2 hours of MCAO, the mice were re-anesthetized, the occlusive suture was removed, and the mice were placed in a temperature-controlled environment.
In experiments to measure oxidative stress, 10 mg/kg dihydroethidium (HE) was injected into the jugular vein at the beginning of MCAO. The mice underwent 2-hour MCAO with continuous monitoring of cerebral blood flow (CBF) by laser-Doppler flowmetry, and at 0 or 2 hours of reperfusion, the mice were sacrificed, perfusion fixed, and the brains harvested.
Regional CBF Assessment
Regional CBF (rCBF) was measured at 60 minutes of ischemia in mice of each genotype and strain, by using [14C]-iodoantipyrine ([14C]-IAP) autoradiography, as previously described . MCAO was carried out as described above, with additional placement of femoral arterial and venous catheters. At 60 minutes of MCAO, arterial blood pressure, pH, PaCO2, and PaO2 were measured, and 4 μCi of [14C]-IAP was infused intravenously. Coronal brain sections (20 μm) cut on a cryostat were exposed to BioMax film (Kodak, Rochester, NY) for 10 days with [14C] standards. From each mouse, we digitized three autoradiographic images from five positions corresponding to coronal sections at +2, +1, 0, -1, and -2 mm from bregma. Regions corresponding to the core anterior cerebral artery (ACA) and MCA territories were outlined in the ipsilateral and contralateral cortex, and signal intensity was determined (ImageJ version 1.36, NIH, Bethesda, MD). rCBF was calculated as previously described , and measurements in the three consecutive coronal slices were averaged at each position to yield values of absolute rCBF in each region.
Fluorescence Microscopy and Quantitative Digital Image Analysis
Following terminal anesthesia, mice were perfused with 3 × weight/volume of normal saline, followed by 4% paraformaldehyde in PBS, and post-fixed in 4% paraformaldehyde and 15% sucrose. For immunofluorescence, 30 μm coronal sections were blocked and quenched with 0.5% H2O2 in 0.3% normal donkey serum in PBS and incubated with primary antibody overnight at 4°C. The samples were incubated with secondary antibody followed by DAB treatment. Slides were counter-stained with fluorescent Nissl reagent to enable identification of intact neurons by presence of the Nissl substance .
Coronal brain sections were examined by confocal microscope LSM510 META (Zeiss, Thornwood, NY). NT, Alexa Fluor 488, and Alexa Fluor 568 were excited with a 405 nm diode laser, a 488 nm Argon laser, and a 561 nm helium-neon laser, respectively. Emission was detected through 420-480-nm, 505-530-nm, and 565-595-nm band-pass filters, respectively. HE was visualized by excitation at 561 nm and emission at 610 nm. An investigator blinded to genotype and hemisphere used Image J software to measure total cPLA2α fluorescence in low magnification (10×) images obtained from representative brain sections of cPLA2α+/+ and cPLA2α-/- mice.
For high resolution analysis, two representative images in the cortical subfield of interest were acquired from each of three brain sections per mouse, and two z-planes of ~2 μm optical thickness separated by 8 μm were sampled. Fluorescence threshold levels were set to allow for recognition of individual neurons in slices without signal saturation and were constant for analysis of all slices. The anatomical regions corresponding to the ischemic core and penumbra were identified in fluorescent Nissl-stained sections. Fluorescence above the threshold was measured in 120-130 neurons for each mouse in non-overlapping, randomly chosen regions in photomicrographs obtained using 100× magnification. Total pixel area was normalized to the total area analyzed and number of neurons and expressed in arbitrary units.
For Western analysis, primary antibodies included COX-2 (1:1000, Cayman Chemical Co. Ann Arbor, MI), cPLA2α (1:500), phospho-cPLA2α (1:500), ERK1/2 and phospho-ERK1/2 (1:1000), MEK1/2 and phospho-MEK1/2 (1:1000), p38 MAPK and phospho-p38 MAPK (1:1000) (all from Cell Signalling Technology, Inc. Danvers, MA). Protein samples were separated by electrophoresis and transferred to PVDF membranes. Immunocomplexes were visualized by enhanced chemiluminescence detection (Amersham Life Science).
Subcellular fractions were prepared from brain tissue homogenized by Dounce (20 strokes) in 10× v/w of ice-cold lysis buffer (2 mM EGTA in PBS with protease inhibitor), and 1/10 volume of benzonase solution (1:50 dilution). The samples were gently shaken on ice for 20 minutes and centrifuged at 800 × g for 10 minutes at 4°C. Supernatant volumes of 100 μl were centrifuged at 100,000 × g for 45 min at 4°C. The supernatants contained the cytosolic fraction. The pelleted nuclear fraction was resuspended in 0.7 w/v CHAPS lysis buffer, sonicated for 10 seconds and incubated on ice for 30 minutes. Protein concentrations were measured by the modified Bradford assay. Cell lysate proteins (25 μg per sample) were electrophoretically resolved on 4-15% polyacrylamide Tris-HCl gradient gels (BioRad, Hercules, CA) and transferred to PVDF membranes. Each membrane was probed and stripped sequentially for phospho-cPLA2α, cPLA2α, and β-actin. For routine immunodetection of proteins cortical hemispheres were homogenized in 5 × v/w buffer, and 10 μg of crude homogenate was used for SDS-PAGE.
Prostaglandin E2 (PGE2) Enzyme Immunoassay
Cortical tissue was weighed and homogenized by polytron in 10 μl/mg wet tissue of ice-cold PBS with 10 μg/ml indomethacin and incubated on ice for 10 min. The homogenate solution was brought to 40% volume aqueous ethanol and acidified with glacial acetic acid to pH 3.0, incubated for 5 min at room temperature, and centrifuged at 2,500 × g for 10 min. The supernatant was applied to a conditioned Oasis HLB column (Waters Corp., Milford, MA), washed with 0.03% formic acid, followed by 15% aqueous ethanol/0.03% formic acid followed by petroleum ether. PGs were eluted with ethyl acetate and evaporated to dryness under nitrogen. The eluant was dissolved in 300 μL assay buffer, and PGE2 concentration was determined by ELISA according to the manufacturer's instructions (Assay Designs, Ann Arbor, MI.). For each extraction and ELISA the results were normalized within the group to account for variation in the efficiency of lipid extraction.
Assays that required multiple samples from a single mouse were analyzed by averaging the intra-mouse samples and then performing statistical annalysis between individuals. For studies in which multiple time points were compared across genotypes and hemispheres analysis was performed by repeated measures ANOVA and post-hoc comparison between genotypes was made with the Newman-Keuls test. Comparison of relative PGE2 concentrations following MCAO between genotypes and hemispheres was conducted with 2-way ANOVA followed by Bonferroni testing between the genotypes using GraphPad Prism version 5.03 (GraphPad Software, San Diego California). Densitometry analysis was by paired t-tests. For all procedures; P < 0.05 was considered statistically significant. Data are expressed as mean ± s.d.
cPLA2α+/+ and -/- neuron size after MCAO, reperfusion or sham surgery
cPLA2α+/+ Neuron Area (arbitrary units)
cPLA2α-/- Neuron Area (arbitrary units)
0 h Reperfuse
1.12 ± 0.21*
1.22 ± 0.30 *
0.55 ± 0.12
0.61 ± 0.15
0.68 ± 0.19
0.72 ± 0.12
0.46 ± 0.12
0.49 ± 0.08
2 h Reperfuse
0.91 ± 0.25
1.08 ± 0.28 *
0.62 ± 0.09
0.67 ± 0.18
0.83 ± 0.26
0.89 ± 0.21
0.53 ± 0.2
0.62 ± 0.11
0.52 ± 0.09
0.60 ± 0.09
0.47 ± 0.13
0.63 ± 0.11
0.40 ± 0.13
0.43 ± 0.09
0.44 ± 0.12
0.45 ± 0.09
Oxidative stress in cPLA2α+/+ and -/- cortex after MCAO, MCAO and reperfusion, or sham surgery
cPLA2α+/+ HE area (relative units)
cPLA2α-/- HE area (relative units)
0 h Reperfuse
45.02 ± 9.58†
38.36 ± 8.53†
6.99 ± 3.88
8.07 ± 4.70
12.76 ± 6.83
12.06 ± 5.85
4.66 ± 4.17
6.27 ± 3.83
2 h Reperfuse
33.01 ± 8.59†
30.70 ± 5.14†
8.82 ± 5.96
9.62 ± 5.95
20..09 ± 5.50
19.47 ± 6.72
6.60 ± 2.98
6.80 ± 4.09
6.32 ± 5.46
6.03 ± 5.03
5.63 ± 3.71
6.40 ± 4.65
4.11 ± 4.48
4.88 ± 5.43
3.85 ± 3.54
5.05 ± 5.67
To determine if differences in ROS levels between cPLA2α+/+ and cPLA2α-/- mice resulted from differences in the vascular responses during ischemia, rCBF was measured by the technique of [14C]-IAP injection. The cortical regions corresponding to the ACA and MCA were demarcated in coronal brain sections. MCAO caused a significant reduction of blood flow in both the ACA and MCA territories, relative to the contralateral sides in each genotype (Figure 6B). CBF was slightly lower in the ipsilateral ACA territory in the anterior region of the cPLA2α-/- brain than in the corresponding region of the cPLA2α+/+ brain. A similar level of ACA blood flow reduction was measured in the anterior regions of the contralateral cortex of cPLA2α-/- mice. Therefore, differences in rCBF between the genotypes during ischemia did not account for the decrease in HE intensity, COX-2, or neuronal loss in the cPLA2α-/- mice.
The cPLA2α amplifies neural injury in animal models of acute and chronic injury, and it is likely that it modulates direct injury and inflammatory pathways [5, 31, 32]. In our previous study, we postulated that reduction of infarct size in cPLA2α-/- mice resulted from a reduction in the delayed extension of injury into the penumbra . In the current study, we measured cPLA2α expression after I/R and compared COX-2 expression, PGE2 levels and ROS formation in the brains of cPLA2α+/+ and cPLA2α-/- mice at different times after reperfusion (0-6 hours). Importantly, these early time points precede the largest influx of circulating inflammatory cells and blood-brain barrier disruption in experimental stroke [7, 33]. Our results show for the first time that ischemia induces cPLA2α expression and this is correlated with COX-2 expression and formation of ROS (as indicated by HE intensity). Taken together, our results indicate that cPLA2α plays an important role in vivo in the early toxic events after I/R.
The changes in the levels of cPLA2α protein that we observed following MCAO, while significant, were small. The reasons for this include the fact that the abundance of cPLA2α compared to other PLA2s in the brain is small . Secondly the proteins used for Western analysis are prepared from tissue samples that include regions where cPLA2α levels may not have changed. This will reduce the observed effect of ischemia on cPLA2α expression. Previously published data support the neuronal induction of cPLA2α following ischemia. Alexandrov and colleagues  identified a hypoxia-sensitive domain in the 5'-untranslated region of the human cPLA2α gene that induces cPLA2α mRNA in brain microvascular endothelial cells. Numerous studies have reported cPLA2α expression in glial cells  and mRNA expression in neurons , and a recent study showed that cPLA2α is expressed in neurons in a mouse model of Alzheimer's disease . After transient global ischemia, late induction of cPLA2α was found only in glial cells . Other investigators have noted an early increase in PLA2 activity minutes after global cerebral I/R . A rat model of transient cerebral ischemia showed that cPLA2α activity increased 1 day after reperfusion but that the levels of protein and phospho-cPLA2α did not increase until 3 days after reperfusion . Changes in cPLA2α that occur hours to days following ischemia may be related to secondary injury and inflammation.
In cell culture models, chemical anoxia  and increased intracellular calcium  cause cPLA2α to translocate to nuclear and other membranes. In our immunofluorescence and subcellular fractionation experiments ischemia did not cause translocation of cPLA2α to membranes. There are several potential explanations for the lack of cPLA2α membrane association. In the gerbil global ischemia model, 5-LO did not translocate to the nucleus until minutes after reperfusion . Similarly, reoxygenation following ischemia appears to be a major determinant of intracellular Ca2+ flux (reviewed by Szydlowska and Tymianski ). Thus, it is possible that cPLA2α translocates to cellular membranes minutes after reperfusion. Further experiments examining the immediate reperfusion period will be necessary to delineate the intracellular signalling events of cPLA2α activation and translocation in neurons.
How could cPLA2α impact neuronal injury at times that precede classical neuroinflammation? Mechanisms including increased PG synthesis and action, modulation of excitotoxic responses and increased ROS stress have been postulated.
The cPLA2α-associated increase in PGE2 levels in cPLA2α+/+ cortex following MCAO are consistent with these postulates. In the ischemic core, we found that neuronal COX-2 induction was delayed and decreased in the cPLA2α-/- mice and that cPLA2α-/- neuronal architecture was preserved. Basal cerebral COX-2 activity and protein levels are significantly decreased in cPLA2α-/- mice , and we previously found that cortical COX-2 and PGE2 responses to lipopolysaccharide were attenuated in cPLA2α-/- mice . Systemic effects of MCAO may explain the increase in PGE2 in both hemispheres following unilateral MCAO. Work from several laboratories indicates that PGE2 signalling through the EP1 or EP3 receptors exacerbates early stroke injury [22, 42–44], perhaps through increased calcium responses . Kunz and colleagues observed that early morphologic changes in neurons represented terminal injury and showed that such injury correlated with COX-2 expression and was dependent on PGE2 and EP1 receptors but not on formation of ROS . Indeed, Miettinen and co-authors used a nonspecific PLA2 inhibitor to ameliorate both injury and COX-2 induction following transient MCAO and suggested that neurons that express cPLA2α are more sensitive to ischemic damage . The coordinated neuronal activities of cPLA2α and COX-2 generate eicosanoids after ischemia which are likely coupled to neuronal G-protein-coupled receptors in a toxic cascade.
Metabolism of AA results in the generation of superoxide, and a detailed kinetic analysis of brain lipids showed decreased AA incorporation in phospholipids of cPLA2α-/- mouse brains . Targeting cPLA2α to the endoplasmic reticulum exacerbates oxidative stress in cultured cells . In the rat, transient global ischemia causes a rapid release of free fatty acids from the cortex that correlates with an increase in cPLA2α activity during the period of ischemia . It is likely that the ischemic cortex of a cPLA2α-/- mouse has less stimulated AA release and therefore less ROS formation. cPLA2α may contribute to ROS formation through an AA-dependent, COX-2 independent pathway.
AA released by cPLA2α also has the potential to significantly affect glutamate excitotoxicity. The application of a cPLA2α inhibitor to cultured hippocampus significantly protected pyramidal neurons from oxygen-glucose deprivation , and PLA2 inhibitors reduced the release of excitatory amino acids from the cortical surface following 4-vessel occlusion in the rat . In cultured neurons, AA amplifies the calcium response to NMDA stimulation . Additionally, we reported that cPLA2α activity causes increased neuronal death, rapid broadening of action potentials, and increased Ca2+ transients following NMDA exposure in the CA1 neurons of acute hippocampal slices . Therefore, it is possible that I/R activates cPLA2α, causing excessive release of AA, which amplifies the processes of excitotoxicity.
The interaction between cPLA2α and the MAP kinase pathways have potential importance in brain I/R injury. Our data demonstrate that cPLA2α enhances ROS formation by MCAO (Figure 7) while others have shown that oxidative stress in mouse embryonic stem cells causes MAPK dependent phosphorylation of cPLA2α . This interaction has the potential to form a positive feedback loop in which cPLA2α-dependent ROS increase kinase activation which leads to further cPLA2α activation. We examined the state of MAPK phosphorylation after 6 hours of reperfusion for several reasons. First, our results demonstrated neuronal injury at this time. Second, Alessandrini and colleagues  showed that in vivo cerebral I/R activates these kinases and that inhibition of MEKs is neuroprotective. Third, similar to our results, 2 hours of MCAO followed by reperfusion in the rat causes phosphorylation of ERK1/2 in both the ipsilateral and contralateral cortex after 6 hours of reperfusion . Lastly, Nito et al. demonstrated that p38 phosphorylation and activity peaked following 2 hours MCAO and 6 hours reperfusion . A reduction in cPLA2α-dependent ROS may explain why p38 MAPK and MEK1/2-ERK1/2 proteins are less phosphorylated in the cPLA2α-/- brain (Figure 7). Oxidative stress activates p38 MAPK in neurons, which then activates caspases 8 and 9 and leads to neuronal apoptosis . Thus the interaction of cPLA2α with p38 MAPK may amplify ischemic injury, as inhibition of p38 activity in the rat decreases phosphorylation of cPLA2α and attenuates stroke injury . It is also possible that AA released by cPLA2α can directly stimulate phosphorylation of p38 MAPK and ERK1/2 since this has been demonstrated in cell lines . Taken together this pathway interaction may potentiate early neurologic injury following MCAO.
The present findings demonstrate that cPLA2α is an important modulator of the molecular events that occur shortly after cerebral I/R. These events are likely to amplify the cascade of inflammation, and cell death that define the process of stroke progression. Our data suggest that the late administration of a cPLA2α inhibitor may have limited efficacy in preventing neurologic injury produced by I/R.
This work was supported by an Anesthesia Departmental Grant, an American Heart Association Grant-in-Aid (AS), and grants from the National Institutes of Health: NS048978 (AS), NS067525 and NS39148 (RCK), AG022971 and NS046400 (SD). The authors thank Takao Shimizu for the gift of the cPLA2α-/- mice. We also thank Claire Levine MS, ELS and Tzipora Sofare, MA, for their careful reading of the manuscript and editorial assistance.
- Muralikrishna Adibhatla R, Hatcher JF: Phospholipase A2, reactive oxygen species, and lipid peroxidation in cerebral ischemia. Free Radic Biol Med. 2006, 40: 376-387. 10.1016/j.freeradbiomed.2005.08.044.View ArticlePubMedGoogle Scholar
- Glover S, de Carvalho MS, Bayburt T, Jonas M, Chi E, Leslie CC, Gelb MH: Translocation of the 85-kDa phospholipase A2 from cytosol to the nuclear envelope in rat basophilic leukemia cells stimulated with calcium ionophore or IgE/antigen. J Biol Chem. 1995, 270: 15359-15367. 10.1074/jbc.270.25.15359.View ArticlePubMedGoogle Scholar
- Clark JD, Milona N, Knopf JL: Purification of a 110-kilodalton cytosolic phospholipase A2 from the human monocytic cell line U937. Proc Natl Acad Sci USA. 1990, 87: 7708-7712. 10.1073/pnas.87.19.7708.PubMed CentralView ArticlePubMedGoogle Scholar
- Kramer RM, Roberts EF, Manetta JV, Hyslop PA, Jakubowski JA: Thrombin-induced phosphorylation and activation of Ca(2+)-sensitive cytosolic phospholipase A2 in human platelets. J Biol Chem. 1993, 268: 26796-26804.PubMedGoogle Scholar
- Bonventre JV, Huang Z, Taheri MR, O'Leary E, Li E, Moskowitz MA, Sapirstein A: Reduced fertility and postischaemic brain injury in mice deficient in cytosolic phospholipase A2. Nature. 1997, 390: 622-625. 10.1038/37635.View ArticlePubMedGoogle Scholar
- Kishimoto K, Matsumura K, Kataoka Y, Morii H, Watanabe Y: Localization of cytosolic phospholipase A2 messenger RNA mainly in neurons in the rat brain. Neuroscience. 1999, 92: 1061-1077. 10.1016/S0306-4522(99)00051-2.View ArticlePubMedGoogle Scholar
- Nito C, Kamada H, Endo H, Niizuma K, Myer DJ, Chan PH: Role of the p38 mitogen-activated protein kinase/cytosolic phospholipase A2 signaling pathway in blood-brain barrier disruption after focal cerebral ischemia and reperfusion. J Cereb Blood Flow Metab. 2008, 28: 1686-1696. 10.1038/jcbfm.2008.60.PubMed CentralView ArticlePubMedGoogle Scholar
- Sanchez-Mejia RO, Newman JW, Toh S, Yu GQ, Zhou Y, Halabisky B, Cisse M, Scearce-Levie K, Cheng IH, Gan L, et al: Phospholipase A2 reduction ameliorates cognitive deficits in a mouse model of Alzheimer's disease. Nat Neurosci. 2008, 11: 1311-1318. 10.1038/nn.2213.PubMed CentralView ArticlePubMedGoogle Scholar
- Fujishima H, Sanchez Mejia RO, Bingham CO, Lam BK, Sapirstein A, Bonventre JV, Austen KF, Arm JP: Cytosolic phospholipase A2 is essential for both the immediate and the delayed phases of eicosanoid generation in mouse bone marrow-derived mast cells. Proc Natl Acad Sci USA. 1999, 96: 4803-4807. 10.1073/pnas.96.9.4803.PubMed CentralView ArticlePubMedGoogle Scholar
- Sapirstein A, Saito H, Texel SJ, Samad TA, O'Leary E, Bonventre JV: Cytosolic phospholipase A2alpha regulates induction of brain cyclooxygenase-2 in a mouse model of inflammation. Am J Physiol Regul Integr Comp Physiol. 2005, 288: R1774-1782.View ArticlePubMedGoogle Scholar
- Bazan NG: Lipid signaling in neural plasticity, brain repair, and neuroprotection. Mol Neurobiol. 2005, 32: 89-103. 10.1385/MN:32:1:089.View ArticlePubMedGoogle Scholar
- Doré S, Otsuka T, Mito T, Sugo N, Hand T, Wu L, Hurn PD, Traystman RJ, Andreasson K: Neuronal overexpression of cyclooxygenase-2 increases cerebral infarction. Ann Neurol. 2003, 54: 155-162. 10.1002/ana.10612.View ArticlePubMedGoogle Scholar
- Iadecola C, Niwa K, Nogawa S, Zhao X, Nagayama M, Araki E, Morham S, Ross ME: Reduced susceptibility to ischemic brain injury and N-methyl-D-aspartate-mediated neurotoxicity in cyclooxygenase-2-deficient mice. Proc Natl Acad Sci USA. 2001, 98: 1294-1299. 10.1073/pnas.98.3.1294.PubMed CentralView ArticlePubMedGoogle Scholar
- Nogawa S, Zhang F, Ross ME, Iadecola C: Cyclo-oxygenase-2 gene expression in neurons contributes to ischemic brain damage. J Neurosci. 1997, 17: 2746-2755.PubMedGoogle Scholar
- Bosetti F, Weerasinghe GR: The expression of brain cyclooxygenase-2 is down-regulated in the cytosolic phospholipase A2 knockout mouse. J Neurochem. 2003, 87: 1471-1477. 10.1046/j.1471-4159.2003.02118.x.View ArticlePubMedGoogle Scholar
- Peters-Golden M: Cell biology of the 5-lipoxygenase pathway. Am J Respir Crit Care Med. 1998, 157: S227-232.View ArticleGoogle Scholar
- Ohtsuki T, Matsumoto M, Hayashi Y, Yamamoto K, Kitagawa K, Ogawa S, Yamamoto S, Kamada T: Reperfusion induces 5-lipoxygenase translocation and leukotriene C4 production in ischemic brain. Am J Physiol. 1995, 268: H1249-1257.PubMedGoogle Scholar
- Iadecola C, Gorelick PB: The Janus face of cyclooxygenase-2 in ischemic stroke: shifting toward downstream targets. Stroke. 2005, 36: 182-185. 10.1161/01.STR.0000153797.33611.d8.View ArticlePubMedGoogle Scholar
- Shen Y, Kishimoto K, Linden DJ, Sapirstein A: Cytosolic phospholipase A2 alpha mediates electrophysiologic responses of hippocampal pyramidal neurons to neurotoxic NMDA treatment. Proc Natl Acad Sci USA. 2007, 104: 6078-6083. 10.1073/pnas.0605427104.PubMed CentralView ArticlePubMedGoogle Scholar
- Kunz A, Anrather J, Zhou P, Orio M, Iadecola C: Cyclooxygenase-2 does not contribute to postischemic production of reactive oxygen species. J Cereb Blood Flow Metab. 2007, 27: 545-551. 10.1038/sj.jcbfm.9600369.View ArticlePubMedGoogle Scholar
- Richards DA, Bliss TV, Richards CD: Differential modulation of NMDA-induced calcium transients by arachidonic acid and nitric oxide in cultured hippocampal neurons. Eur J Neurosci. 2003, 17: 2323-2328. 10.1046/j.1460-9568.2003.02671.x.View ArticlePubMedGoogle Scholar
- Ahmad AS, Saleem S, Ahmad M, Doré S: Prostaglandin EP1 receptor contributes to excitotoxicity and focal ischemic brain damage. Toxicol Sci. 2006, 89: 265-270. 10.1093/toxsci/kfj022.View ArticlePubMedGoogle Scholar
- Kawano T, Anrather J, Zhou P, Park L, Wang G, Frys KA, Kunz A, Cho S, Orio M, Iadecola C: Prostaglandin E2 EP1 receptors: downstream effectors of COX-2 neurotoxicity. Nat Med. 2006, 12: 225-229. 10.1038/nm1362.View ArticlePubMedGoogle Scholar
- Arai K, Ikegaya Y, Nakatani Y, Kudo I, Nishiyama N, Matsuki N: Phospholipase A2 mediates ischemic injury in the hippocampus: a regional difference of neuronal vulnerability. Eur J Neurosci. 2001, 13: 2319-2323. 10.1046/j.0953-816x.2001.01623.x.View ArticlePubMedGoogle Scholar
- Brady KM, Texel SJ, Kishimoto K, Koehler RC, Sapirstein A: Cytosolic phospholipase A2 alpha modulates NMDA neurotoxicity in mouse hippocampal cultures. Eur J Neurosci. 2006, 24: 3381-3386. 10.1111/j.1460-9568.2006.05237.x.View ArticlePubMedGoogle Scholar
- Jay TM, Lucignani G, Crane AM, Jehle J, Sokoloff L: Measurement of local cerebral blood flow with [14C]iodoantipyrine in the mouse. J Cereb Blood Flow Metab. 1988, 8: 121-129.View ArticlePubMedGoogle Scholar
- Quinn B, Toga AW, Motamed S, Merlic CA: Fluoro nissl green: a novel fluorescent counterstain for neuroanatomy. Neurosci Lett. 1995, 184: 169-172. 10.1016/0304-3940(94)11198-R.View ArticlePubMedGoogle Scholar
- Miettinen S, Fusco FR, Yrjanheikki J, Keinanen R, Hirvonen T, Roivainen R, Narhi M, Hokfelt T, Koistinaho J: Spreading depression and focal brain ischemia induce cyclooxygenase-2 in cortical neurons through N-methyl-D-aspartic acid-receptors and phospholipase A2. Proc Natl Acad Sci USA. 1997, 94: 6500-6505. 10.1073/pnas.94.12.6500.PubMed CentralView ArticlePubMedGoogle Scholar
- Marcheselli VL, Hong S, Lukiw WJ, Tian XH, Gronert K, Musto A, Hardy M, Gimenez JM, Chiang N, Serhan CN, Bazan NG: Novel docosanoids inhibit brain ischemia-reperfusion-mediated leukocyte infiltration and pro-inflammatory gene expression. J Biol Chem. 2003, 278: 43807-43817. 10.1074/jbc.M305841200.View ArticlePubMedGoogle Scholar
- Alessandrini A, Namura S, Moskowitz MA, Bonventre JV: MEK1 protein kinase inhibition protects against damage resulting from focal cerebral ischemia. Proc Natl Acad Sci USA. 1999, 96: 12866-12869. 10.1073/pnas.96.22.12866.PubMed CentralView ArticlePubMedGoogle Scholar
- Klivenyi P, Beal MF, Ferrante RJ, Andreassen OA, Wermer M, Chin MR, Bonventre JV: Mice deficient in group IV cytosolic phospholipase A2 are resistant to MPTP neurotoxicity. J Neurochem. 1998, 71: 2634-2637. 10.1046/j.1471-4159.1998.71062634.x.View ArticlePubMedGoogle Scholar
- Kalyvas A, David S: Cytosolic phospholipase A2 plays a key role in the pathogenesis of multiple sclerosis-like disease. Neuron. 2004, 41: 323-335. 10.1016/S0896-6273(04)00003-0.View ArticlePubMedGoogle Scholar
- Candelario-Jalil E, Gonzalez-Falcon A, Garcia-Cabrera M, Leon OS, Fiebich BL: Post-ischaemic treatment with the cyclooxygenase-2 inhibitor nimesulide reduces blood-brain barrier disruption and leukocyte infiltration following transient focal cerebral ischaemia in rats. J Neurochem. 2007, 100: 1108-1120. 10.1111/j.1471-4159.2006.04280.x.View ArticlePubMedGoogle Scholar
- Yang HC, Mosior M, Johnson CA, Chen Y, Dennis EA: Group-specific assays that distinguish between the four major types of mammalian phospholipase A2. Anal Biochem. 1999, 269: 278-288. 10.1006/abio.1999.4053.View ArticlePubMedGoogle Scholar
- Alexandrov PN, Cui JG, Lukiw WJ: Hypoxia-sensitive domain in the human cytosolic phospholipase A2 promoter. Neuroreport. 2006, 17: 303-307. 10.1097/01.wnr.0000201506.61373.99.View ArticlePubMedGoogle Scholar
- Sun GY, Xu J, Jensen MD, Yu S, Wood WG, Gonzalez FA, Simonyi A, Sun AY, Weisman GA: Phospholipase A2 in astrocytes: responses to oxidative stress, inflammation, and G protein-coupled receptor agonists. Mol Neurobiol. 2005, 31: 27-41. 10.1385/MN:31:1-3:027.View ArticlePubMedGoogle Scholar
- Clemens JA, Stephenson DT, Smalstig EB, Roberts EF, Johnstone EM, Sharp JD, Little SP, Kramer RM: Reactive glia express cytosolic phospholipase A2 after transient global forebrain ischemia in the rat. Stroke. 1996, 27: 527-535.View ArticlePubMedGoogle Scholar
- Rordorf G, Uemura Y, Bonventre JV: Characterization of phospholipase A2 (PLA2) activity in gerbil brain: enhanced activities of cytosolic, mitochondrial, and microsomal forms after ischemia and reperfusion. J Neurosci. 1991, 11: 1829-1836.PubMedGoogle Scholar
- Sheridan AM, Sapirstein A, Lemieux N, Martin BD, Kim DK, Bonventre JV: Nuclear translocation of cytosolic phospholipase A2 is induced by ATP depletion. J Biol Chem. 2001, 276: 29899-29905. 10.1074/jbc.M103758200.View ArticlePubMedGoogle Scholar
- Evans JH, Spencer DM, Zweifach A, Leslie CC: Intracellular calcium signals regulating cytosolic phospholipase A2 translocation to internal membranes. J Biol Chem. 2001, 276: 30150-30160. 10.1074/jbc.M100943200.View ArticlePubMedGoogle Scholar
- Szydlowska K, Tymianski M: Calcium, ischemia and excitotoxicity. Cell Calcium. 47: 122-129. 10.1016/j.ceca.2010.01.003.Google Scholar
- Ahmad M, Saleem S, Zhuang H, Ahmad AS, Echeverria V, Sapirstein A, Doré S: 1-hydroxyPGE reduces infarction volume in mouse transient cerebral ischemia. Eur J Neurosci. 2006, 23: 35-42. 10.1111/j.1460-9568.2005.04540.x.View ArticlePubMedGoogle Scholar
- Manabe Y, Anrather J, Kawano T, Niwa K, Zhou P, Ross ME, Iadecola C: Prostanoids, not reactive oxygen species, mediate COX-2-dependent neurotoxicity. Ann Neurol. 2004, 55: 668-675. 10.1002/ana.20078.View ArticlePubMedGoogle Scholar
- McCullough L, Wu L, Haughey N, Liang X, Hand T, Wang Q, Breyer RM, Andreasson K: Neuroprotective function of the PGE2 EP2 receptor in cerebral ischemia. J Neurosci. 2004, 24: 257-268. 10.1523/JNEUROSCI.4485-03.2004.View ArticlePubMedGoogle Scholar
- Rosenberger TA, Villacreses NE, Contreras MA, Bonventre JV, Rapoport SI: Brain lipid metabolism in the cPLA2 knockout mouse. J Lipid Res. 2003, 44: 109-117. 10.1194/jlr.M200298-JLR200.View ArticlePubMedGoogle Scholar
- Ren G, Takano T, Papillon J, Cybulsky AV: Cytosolic phospholipase A2-alpha enhances induction of endoplasmic reticulum stress. Biochim Biophys Acta. 1803: 468-481.Google Scholar
- Saluja I, Song D, O'Regan MH, Phillis JW: Role of phospholipase A2 in the release of free fatty acids during ischemia-reperfusion in the rat cerebral cortex. Neurosci Lett. 1997, 233: 97-100. 10.1016/S0304-3940(97)00646-0.View ArticlePubMedGoogle Scholar
- Phillis JW, O'Regan MH: Mechanisms of glutamate and aspartate release in the ischemic rat cerebral cortex. Brain Res. 1996, 730: 150-164.View ArticlePubMedGoogle Scholar
- Lee SH, Na SI, Heo JS, Kim MH, Kim YH, Lee MY, Kim SH, Lee YJ, Han HJ: Arachidonic acid release by H2O2 mediated proliferation of mouse embryonic stem cells: involvement of Ca2+/PKC and MAPKs-induced EGFR transactivation. J Cell Biochem. 2009, 106: 787-797. 10.1002/jcb.22013.View ArticlePubMedGoogle Scholar
- Lennmyr F, Karlsson S, Gerwins P, Ata KA, Terent A: Activation of mitogen-activated protein kinases in experimental cerebral ischemia. Acta Neurol Scand. 2002, 106: 333-340. 10.1034/j.1600-0404.2002.01313.x.View ArticlePubMedGoogle Scholar
- Choi WS, Eom DS, Han BS, Kim WK, Han BH, Choi EJ, Oh TH, Markelonis GJ, Cho JW, Oh YJ: Phosphorylation of p38 MAPK induced by oxidative stress is linked to activation of both caspase-8- and -9-mediated apoptotic pathways in dopaminergic neurons. J Biol Chem. 2004, 279: 20451-20460. 10.1074/jbc.M311164200.View ArticlePubMedGoogle Scholar
- Paine E, Palmantier R, Akiyama SK, Olden K, Roberts JD: Arachidonic acid activates mitogen-activated protein (MAP) kinase-activated protein kinase 2 and mediates adhesion of a human breast carcinoma cell line to collagen type IV through a p38 MAP kinase-dependent pathway. J Biol Chem. 2000, 275: 11284-11290. 10.1074/jbc.275.15.11284.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.